Literature DB >> 18415382

[Drug treatment as migraine prophylaxis.].

H C Diener1, A Ziegler.   

Abstract

If migraine attacks occur more frequently than 2 times a month, treatment of the acute attack with analgesics and ergotamine becomes problematic. An acute relief of migraine symptoms will be achieved only at the risk of developing a drug-induced chronic headache. Therefore, if migraine attacks occur frequently prophylactic treatment should be considered. A bewildering variety of drugs have been discussed for migraine prophylaxis in the past few decades. Only a few of them can be accepted to be effective on the basis of reliable clinical studies. Others have failed to show any superiority to placebo treatment when tested in controlled drug trials for a period long enough to rule out the placebo response, which may simulate effectiveness at the beginning of the trial. The efficacy of metoprolol and propranolol has been demonstrated beyond any doubt. It seems, however, that other beta-blocking drugs are less effective or even ineffective. In more than 20% of patients even prolonged treatment with metoprolol or propranolol does not provide sufficient relief. Flunarizine may be tried in these patients, as long as side effects do not occur or can be tolerated by the patient. Whether non-steroidal antirheumatics and dihydroergotamine can be considered as an effective and safe alternative in migraine prophylaxis is still not well established. There is, however, convincing evidence that neither clonidine, nor anti-histamines, nor barbiturates, nor antiepileptic drugs, nor anxiolytics are effective in the prophylactic treatment of migraine. Successful prophylactic treatment cannot be achieved by drug therapy alone. Any form of drug treatment should be complemented by providing the patient with detailed information about the nature of the disease and the properties of the prescribed drugs, as well as careful investigation of the patient's situation and habits and a careful search for precipitants, combined with an attempt to change the patient's habits and to avoid factors that trigger the attacks.

Entities:  

Year:  1989        PMID: 18415382     DOI: 10.1007/BF02527386

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  34 in total

1.  Propranolol for migraine prophylaxis.

Authors:  B Forssman; K G Henriksson; V Johannsson; L Lindvall; H Lundin
Journal:  Headache       Date:  1976-11       Impact factor: 5.887

2.  Analgesic-induced chronic headache: long-term results of withdrawal therapy.

Authors:  H C Diener; J Dichgans; E Scholz; S Geiselhart; W D Gerber; A Bille
Journal:  J Neurol       Date:  1989-01       Impact factor: 4.849

3.  Long acting propranolol in the prophylaxis of migraine. Comparison of the daily doses of 80 mg and 160 mg.

Authors:  H Havanka-Kanniainen; E Hokkanen; V V Myllylä
Journal:  Headache       Date:  1988-10       Impact factor: 5.887

4.  Flunarizine, a calcium entry blocker in migraine prophylaxis.

Authors:  W K Amery; L I Caers; T J Aerts
Journal:  Headache       Date:  1985-07       Impact factor: 5.887

5.  Prophylactic treatment of classical and non-classical migraine with metoprolol--a comparison with placebo.

Authors:  P G Andersson; S Dahl; J H Hansen; P E Hansen; C Hedman; T N Kristensen; B de Fine Olivarius
Journal:  Cephalalgia       Date:  1983-12       Impact factor: 6.292

Review 6.  Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine.

Authors:  W K Amery
Journal:  Headache       Date:  1983-03       Impact factor: 5.887

7.  Nimodipine, a new calcium antagonist, in the prophylactic treatment of migraine.

Authors:  H J Gelmers
Journal:  Headache       Date:  1983-05       Impact factor: 5.887

8.  A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine.

Authors:  P Louis
Journal:  Headache       Date:  1981-11       Impact factor: 5.887

9.  Flunarizine- and cinnarizine-induced extrapyramidal reactions.

Authors:  F Micheli; M F Pardal; M Gatto; M Torres; G Paradiso; I C Parera; R Giannaula
Journal:  Neurology       Date:  1987-05       Impact factor: 9.910

10.  Propranolol plasma levels and relief of migraine. Relationship between plasma propranolol and 4-hydroxypropranolol concentrations and clinical effects.

Authors:  P Cortelli; T Sacquegna; F Albani; A Baldrati; R D'Alessandro; A Baruzzi; E Lugaresi
Journal:  Arch Neurol       Date:  1985-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.